0 CHECKOUT

Post Menopausal Osteoporosis - Pipeline Review, H1 2015

  • ID: 3259647
  • April 2015
  • 86 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Oncobiologics, Inc.
  • Pfizer Inc.
  • Radius Health, Inc.
  • MORE

Post Menopausal Osteoporosis - Pipeline Review, H1 2015

Summary

This, ‘Post Menopausal Osteoporosis - Pipeline Review, H1 2015’, provides an overview of the Post Menopausal Osteoporosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Post Menopausal Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Oncobiologics, Inc.
  • Pfizer Inc.
  • Radius Health, Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Post Menopausal Osteoporosis Overview
Therapeutics Development
Pipeline Products for Post Menopausal Osteoporosis - Overview
Pipeline Products for Post Menopausal Osteoporosis - Comparative Analysis
Post Menopausal Osteoporosis - Therapeutics under Development by Companies
Post Menopausal Osteoporosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Post Menopausal Osteoporosis - Products under Development by Companies
Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development
Amgen Inc.
Chronos Therapeutics Limited
Eli Lilly and Company
Hanmi Pharmaceuticals, Co. Ltd.
Merck & Co., Inc.
Oncobiologics, Inc.
Paras Biopharmaceuticals Finland Oy
Pfizer Inc.
Radius Health, Inc.
Unigene Laboratories, Inc.
Post Menopausal Osteoporosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(aceclofenac + eperisone) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
abaloparatide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bazedoxifene acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
blosozumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
calcitonin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
denosumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
denosumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs for Postmenopausal Osteoporosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
odanacatib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDC-5 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
romosozumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
teriparatide biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Post Menopausal Osteoporosis - Recent Pipeline Updates
Post Menopausal Osteoporosis - Dormant Projects
Post Menopausal Osteoporosis - Discontinued Products
Post Menopausal Osteoporosis - Product Development Milestones
Featured News & Press Releases
Jan 29, 2015: Radius Health Announces Oral Presentation of the ACTIVE Phase 3 Clinical Trial of Abaloparatide-SC for Postmenopausal Women With Osteoporosis at ICE/ENDO 2015
Dec 21, 2014: Radius Announces Positive Phase 3 Top-Line Results for Its Investigational Drug Abaloparatide-SC in Postmenopausal Women With Severe Osteoporosis
Nov 24, 2014: The Journal of Clinical Endocrinology & Metabolism Publishes Radius Health's Phase II Study of the Investigational Drug Abaloparatide in Postmenopausal Women With Osteoporosis
Sep 15, 2014: Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia (Denosumab) In Postmenopausal Women With Osteoporosis
Sep 15, 2014: Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis
Sep 15, 2014: New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density
Aug 13, 2014: Tarsa Therapeutics Secures $10 Million And Adds Industry Veteran Daniel Soland As A Director
Jan 09, 2014: Radius Announces Positive Topline Data From Phase 2 Study of Abaloparatide (BA058) for Postmenopausal Osteoporosis Using Two Delivery Systems
Jan 02, 2014: Romosozumab phase 2 data published in New England Journal of Medicine show significant increases in bone mineral density at both spine and hip
Dec 31, 2013: Romosozumab Phase 2 Data Published In New England Journal Of Medicine Show Significant Increases In Bone Mineral Density At Both Spine And Hip
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Post Menopausal Osteoporosis, H1 2015
Number of Products under Development for Post Menopausal Osteoporosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Post Menopausal Osteoporosis - Pipeline by Amgen Inc., H1 2015
Post Menopausal Osteoporosis - Pipeline by Chronos Therapeutics Limited, H1 2015
Post Menopausal Osteoporosis - Pipeline by Eli Lilly and Company, H1 2015
Post Menopausal Osteoporosis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015
Post Menopausal Osteoporosis - Pipeline by Merck & Co., Inc., H1 2015
Post Menopausal Osteoporosis - Pipeline by Oncobiologics, Inc., H1 2015
Post Menopausal Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2015
Post Menopausal Osteoporosis - Pipeline by Pfizer Inc., H1 2015
Post Menopausal Osteoporosis - Pipeline by Radius Health, Inc., H1 2015
Post Menopausal Osteoporosis - Pipeline by Unigene Laboratories, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Post Menopausal Osteoporosis Therapeutics - Recent Pipeline Updates, H1 2015
Post Menopausal Osteoporosis - Dormant Projects, H1 2015
Post Menopausal Osteoporosis - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Post Menopausal Osteoporosis, H1 2015
Number of Products under Development for Post Menopausal Osteoporosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Amgen Inc.
Chronos Therapeutics Limited
Eli Lilly and Company
Hanmi Pharmaceuticals, Co. Ltd.
Merck & Co., Inc.
Oncobiologics, Inc.
Paras Biopharmaceuticals Finland Oy
Pfizer Inc.
Radius Health, Inc.
Unigene Laboratories, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Actavis
  • Smith & Nephew PLC.
  • Bayer AG
  • Hologic Inc.
  • Abbott Laboratories Ltd.
  • Polpharma SA